BACKGROUND: Breast cancer (BC) disparities may widen with genomic advances. The authors compared non-Hispanic white (NHW), black, and Hispanic BC survivors for 1) cancer risk-management practices among BRCA carriers and 2) provider discussion and receipt of genetic testing. METHODS: A population-based sample of NHW, black, and Hispanic women who had been diagnosed with invasive BC at age 50 years or younger from 2009 to 2012 were recruited through the state cancer registry. Multiple logistic regression was used to compare cancer risk-management practices in BRCA carriers and associations of demographic and clinical variables with provider discussion and receipt of testing. RESULTS: Of 1622 participants, 159 of 440 (36.1%) black women, 579 of 897 (64.5%) NHW women, 58 of 117 (49.6%) Spanish-speaking Hispanic women, and 116 of 168 (69%) English-speaking Hispanic women underwent BRCA testing, of whom 90 had a pathogenic BRCA mutation identified. Among BRCA carriers, the rates of risk-reducing mastectomy and risk-reducing salpingo-oophorectomy were significantly lower among black women compared with Hispanic and NHW women after controlling for clinical and demographic variables (P 5 .025 and P 5 .008, respectively). Compared with NHW women, discussion of genetic testing with a provider was 16 times less likely among black women (P < .0001) and nearly 2 times less likely among Spanish-speaking Hispanic women (P 5 .04) after controlling for clinical and sociodemographic factors. CONCLUSIONS: The current results suggest that the rates of risk-reducing salpingo-oophorectomy are lower among black BRCA carriers compared with their Hispanic and NHW counterparts, which is concerning because benefits from genetic testing arise from cancer risk-management practice options. Furthermore, lower BRCA testing rates among blacks may partially be because of a lower likelihood of provider discussion. Future studies are needed to improve cancer risk identification and management practices across all populations to prevent the widening of disparities. Cancer 2017;123:2497-505. V C 2017 American Cancer Society.
INTRODUCTION
Breast cancer (BC) is the most common cancer among women in the United States, with 5% to 10% caused by inherited gene mutations most commonly in the breast cancer genes BRCA1 and BRCA2 (BRCA) genes.
1,2 BRCA mutation carriers have a 60% to 70% lifetime risk of BC and up to a 44% risk of ovarian cancer [3] [4] [5] [6] compared with lifetime risks of 12% and <2% for women in the general population, respectively. Furthermore, the risk of a second primary BC among BRCA mutation carriers may be >50%, particularly among those who develop their first BC at an early age. 7, 8 These risks may be reduced by 90% or more (ie, to below that of the general population) through preventive options, such as risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO). 9, 10 Once an individual has been tested for and identified with an inherited cancer predisposition, they will only reap health benefits from acting on this information. Consequently, clinical practice guidelines in the United States for BRCA carriers have been developed through the National Comprehensive Cancer Network (NCCN), including: 1) annual BC surveillance (through mammogram and breast magnetic resonance imaging [MRI] ) or RRM for BC risk management, and 2) RRSO for ovarian cancer risk management. 11 Prior efforts to explore cancer risk-management practices among BRCA carriers have primarily been based on nonHispanic white (NHW) populations at academic institutions [12] [13] [14] [15] or integrated health systems. 16 Studies among USbased women consistently suggest higher RRSO rates (approximately 70%) compared with RRM (approximately 40%). [12] [13] [14] [15] [16] Yet no prior efforts have compared cancer risk-management across ethnically and racially diverse populations with BRCA mutations treated across varied settings.
The identification of a BRCA mutation has potential to empower women with options to detect cancers early or prevent them altogether. [17] [18] [19] Yet only approximately 10% of those with BRCA mutations in the United States are aware that they carry a mutation. 20 Furthermore, there are substantial disparities across populations in awareness and use of genetic testing for inherited BC, with considerably lower rates reported among blacks and Hispanics compared with NHWs. [21] [22] [23] [24] According to NCCN guidelines, all women diagnosed with BC aged 50 years should be offered cancer genetic risk assessment (which includes genetic counseling and consideration for testing), 11 yet few discuss testing with their health care provider. [25] [26] [27] [28] Through a population-based sample of young black, Hispanic, and NHW women with BC, we sought to compare: 1) cancer risk-management practices among BRCA carriers, and 2) provider discussion and receipt of genetic testing.
MATERIALS AND METHODS

Participants
Eligible participants were women who had been diagnosed with invasive BC at age 50 years or younger between the years 2009 and 2012, were living in Florida at the time of diagnosis, and were alive at the time of recruitment. Through protocols approved by the institutional review boards at the University of South Florida and the Florida Department of Health, recruitment of black women was initiated in 2012, as previously described, 29, 30 and recruitment of white and Hispanic women was initiated in 2014. By using information on all eligible participants released by the Florida State Cancer Registry, contact was attempted among all black and Hispanic women in the sampling frame and in a random sample of white women (Fig. 1 ).
Participants were recruited using previously described, state-mandated recruitment methods, 29, 30 which consisted of 2 mailings, 3 weeks apart, including a "telephone response card" to give potential participants the option to either decline (ie, indicating they did not wish to be contacted by phone) or express interest in participation with follow-up by a study team member. If no response was received within 3 weeks of the second mailing, then a member of the study team attempted to contact the potential participant by telephone to explain the study and determine their interest in participation. For those willing to participate, written informed consent was obtained, and a baseline study questionnaire was completed.
Measures
Clinical (ie, age at diagnosis, stage of diagnosis, histologic subtype, tumor receptor status) and demographic (ie, primary payer at diagnosis, race/ethnicity) data were obtained from the cancer registry for all potential participants who met inclusion criteria. Tumor receptor status was coded as triple-negative if registry data indicated that the tumor was negative for all 3 receptors (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2) or nontriple-negative if at least 1 of these receptors was present. Tumors that were missing data for 1 or more receptors but were negative for the other receptors were categorized as undetermined. For all participants in the undetermined group, clarification was attempted through medical record verification and patient self-report. Data obtained through the baseline questionnaire included health care provider discussion of genetic testing for inherited cancer risk and receipt of BRCA testing. Medical record verification was attempted in all participants who indicated receipt of BRCA testing for whom a signed a medical release was available. Participants were categorized through self-reported race/ethnicity into NHW, black, and Hispanic groups. Hispanics were further categorized as Spanish-speaking (if they spoke Spanish at home) or English-speaking (all others). Additional information obtained through the baseline questionnaire included: partner status, biologic children, income, family cancer history, education, insurance status, cancer risk management (including receipt of an RRSO, RRM), and high-risk BC screening (mammograms and breast MRIs).
Data Analysis
Demographic and clinical characteristics available through the cancer registry for all eligible participants were summarized for each racial/ethnic strata using descriptive statistics. Consented participants in each racial/ ethnic strata were compared with all other presumed eligible women from the cancer registry using Pearson chisquare tests. For participants in each of the 4 racial/ethnic groups, demographic and clinical characteristics were summarized and compared using Pearson chi-square tests for categorical variables and Mann-Whitney tests for continuous variables.
Among those who had a known BRCA mutation at the time of the baseline questionnaire, proportions who received RRSO, RRM, and breast surveillance were calculated based on self-report. Comparisons between blacks, Hispanics and NHWs were made using multiple logistic regression to control for age at enrollment, time since diagnosis, income, family history of breast and ovarian cancer, and private insurance at diagnosis. Analyses were conducted using SAS version 9.4. The goodness-of-fit for all regression models was evaluated with the HosmerLemeshow statistic. For all analyses, a 2-sided P value < 0.05 was considered statistically significant.
The proportions of women who discussed genetic testing with a health care provider and of those who underwent genetic testing were calculated for each racial/ ethnic strata. Two multiple logistic regression models were then conducted using the 1325 women for whom all data were available. The first regression model evaluated racial/ethnic differences in genetic testing discussion, and the second model evaluated receipt of genetic testing. To simultaneously control for key variables and evaluate the relative strength of the relation between the 2 outcomes (ie, discussed testing and received testing), a path model was conducted using Mplus version 6.12. Variables with a P value < .15 from the 2 logistic regression models were included in the model as follows: race/ethnicity, having children, diagnosed at age 45 years or younger, annual income >$25,000, college educated, family history of breast cancer, and having private insurance were included as predictors of having testing. Simultaneously, race/ethnicity, having children, triple-negative tumor, diagnosed at or age 45 years or younger, annual income >$25,000, college educated, family history of breast cancer, family history of ovarian cancer, having private insurance, and years from diagnosis to survey were included as predictors for receipt of testing. A direct path was included to evaluate the strength of the relation between discussed testing and receipt of testing while controlling for all other variables specified in the path model.
RESULTS
Participants included a total of 1622 BC survivors, consisting of 440 blacks, 168 English-speaking Hispanics, 117 Spanish-speaking Hispanics, and 897 NHWs (Fig.  1) . Comparisons between participants and all others within each respective racial/ethnic strata revealed no statistically significant differences with regard to median age, stage, histologic subtype, marital status, or employment at diagnosis (results not shown). Among those who reported genetic testing, medical record verification was obtained in 72% overall and in 78% of BRCA carriers. Participants differed across racial/ethnic strata on several clinical and demographic variables (Table 1) .
Among NHW, black, and Hispanic BRCA carriers: 1) uptake of RRSO was 76.6%, 28.1%, and 90.9%, respectively; 2) uptake of RRM was 95.7%, 68.8%, and 81.8%, respectively; and 3) uptake of guideline-based BC screening or RRM was 100%, 85.7%, and 100%, respectively (Fig. 2) . Among BRCA carriers with remaining breast tissue who reported no breast screening, 2 had not yet completed their BC treatment, both of whom were black. With blacks as the referent group, even after controlling for possible confounders, Hispanics and NHWs remained significantly more likely to undergo RRSO (P 5 .025) and RRM (P 5 .008). Hosmer-Lemeshow tests provided evidence of adequate model fit for all logistic regression models (all P > .05).
All participants met national guidelines for genetic risk assessment and counseling 11 ; however, among blacks, Spanish-speaking Hispanics, English-speaking Hispanics, and NHWs, the proportion who reported having discussed genetic testing with a provider was 37.3%, 70.1%, 85.7%, and 85.7%, respectively; and the proportion who reported receipt of genetic testing was 36.1%, 49.6%, 69.05%, and 64.55%, respectively. Compared with NHWs, blacks were 16.6 times less likely to have discussed genetic testing with a health care provider (P < .0001), and Spanish-speaking Hispanics were nearly 2 times less likely to have discussed testing (P 5 .04) after controlling for other variables ( Table 2) . Rates of genetic testing discussion were similar among NHWs and primarily English-speaking Hispanics. Blacks were 5.6 times less likely to have had genetic testing than NHWs when controlling for other variables (Table 2 ), but differences between NHWs and Spanishspeaking Hispanics were no longer significant (P 5 .82) after controlling for clinical and socioeconomic differences. The path model revealed that the strongest association with receipt of testing was having a health care provider discuss testing (Fig. 3) .
DISCUSSION
To our knowledge, this is the first study to compare differences in cancer risk-management practices across an ethnically and racially diverse sample of BRCA mutation carriers who were tested and treated across multiple settings. Our findings suggest lower rates of RRSO and RRM among blacks. Furthermore, our results demonstrate lower genetic testing rates among blacks compared with NHWs, most strongly associated with lower genetic testing discussions by health care providers.
When considering BRCA testing, it is important to recognize that benefits do not arise from BRCA testing itself but, rather, from acting on test results to detect cancers early or prevent them altogether. Several studies have evaluated cancer-risk management practices among BRCA carriers; however, these primarily encompass NHW populations mainly based at academic 16 A recent retrospective cohort study of primarily NHW BRCA carriers from a community health care system in Northern California reported uptake of RRSO and RRM among BRCA carriers of 74% and 44%, respectively, 16 which are slightly higher than the rates recently reported from USbased academic centers. 12, 15 Similarly, uptake of preventive options reported through an international study of BRCA carriers reported RRSO and RRM rates of 71.1% and 36.3%, respectively, among US-based women. 13 Taken together, these RRSO rates are similar to those observed in our study among NHWs and Hispanics yet substantially higher than the RRSO rate of 28% observed among blacks in our study. Consistent with the low RRSO rates we observed among blacks are results from African American BRCA carriers in whom breast and ovarian cancer surveillance was preferred over riskreducing surgery; however that earlier study was based on a single African American kindred. 31 Consequently, our study represents the first to evaluate and compare followup care among unselected BRCA carriers across minority populations, with results suggesting substantial racial differences in cancer risk-management practices.
Although RRSO remains the only reliable option for ovarian cancer risk-management among BRCA carriers, RRM or heightened screening through annual MRI and mammograms are both considered appropriate options for BC risk management. 11 However, adherence to screening over time among unaffected BRCA carriers in an integrated health care system identified low compliance with annual MRI (35%) and mammograms (43%) at baseline among those who did not undergo RRM, with compliance at 5 years dropping to only 3% and 7%, respectively. 16 More recently, a follow-up study of primarily NHW BRCA carriers who received genetic counseling and BRCA testing through an academic center indicated that 51% underwent RRM and 72% underwent RRSO. 32 It is noteworthy that, despite the limited number of minorities in the study (approximately 11%; n 5 11), the authors reported that both white race and greater knowledge about BC genetics were significantly associated with adherence to recommended management, highlighting the potential for genomic testing to widen existing disparities among minority populations. Ultimately, to our knowledge, our study is the sole population-based effort to compare differences in cancer risk-management practices across minority BRCA carriers who received treatment across diverse settings, underscoring the need for further studies to confirm and address the observed disparities in follow-up care.
The majority of BRCA testing has occurred in Caucasian populations, 24, [33] [34] [35] [36] with disproportionately lower rates among blacks and Hispanics, 23, 24, 36 consistent with our results among blacks and Spanish-speaking Hispanics. However, English-speaking Hispanics and NHWs had similar testing rates, which may reflect acculturation of Hispanics over generations. Black women in our study were not recent immigrants and did not have a language barrier, yet their testing rates were the lowest, demonstrating a concerning health disparity that requires focused attention. This is particularly alarming given that limited studies among high-risk Hispanics [37] [38] [39] [40] and blacks 41 suggest high interest in these services once they are explained to them.
Reasons for lower testing rates among blacks and Hispanics include both lower awareness about genetic testing 21 and access to cancer genetics experts, 42 geographic barriers, 43 language barriers, 44 and socioeconomic factors, such as insurance, education, and income. 45 In fact, the presence of private insurance had a direct impact on both genetic testing discussion and receipt of testing in the path model (Fig. 3) . On the basis of our own clinical experience, this is not surprising, because private insurers tend to be more likely to cover genetic testing than Medicaid. In addition, a genetic test discussion may not even occur if testing is not perceived to be feasible by patients or providers, which might be the case if the patient is uninsured or on Medicaid. In our study, even after controlling for socioeconomic factors, blacks were less likely to be tested, but the single strongest predictor was provider discussion of genetic testing. Consequently, in addition to patient-level factors, provider-level and system-level factors may contribute to suboptimal testing rates among minorities. In particular, multiple studies demonstrate the importance of health care provider recommendations in receipt of genetic testing, and lack of physician referral is among the most highly cited barriers to testing among BC survivors. 23, 34, [46] [47] [48] [49] Our findings that health care provider discussion of testing was the strongest predictor for receipt of BRCA, testing with lowest rates of both testing discussion and testing receipt among blacks, are consistent with prior studies. Although they were not explored in our study, other potential explanations for observed differences include provider characteristics and distribution as well as variability in clinical practice situations, which should be explored further through future efforts. Ultimately, our findings are concerning and suggest the need to develop multilevel interventions targeted at both the patient and the provider levels to successfully address the widening disparities because of genomic advances.
The current study has several strengths, including the first population-based design to systematically compare cancer risk-management practices among BRCA carriers drawn from an ethnically and racially diverse sample of BC survivors who were treated across multiple settings, enhancing the generalizability of our findings. Furthermore, our estimates of provider discussion and genetic testing across diverse populations provides updated and novel data compared with prior efforts that had limited minority representation, nonpopulation-based sampling, or a sampling frame of women diagnosed before 2008. 23, 34, [46] [47] [48] [49] Furthermore, BRCA testing confirmation in over 72% of all women further strengthens the accuracy and validity of our observations. Despite these strengths, there remain some limitations, including our inability to fully determine reasons for the observed differences in uptake of cancer riskmanagement options and testing rates across populations. Although participants were diagnosed within the same 4 years, and eligibility criteria were the same, the blacks and nonblacks were recruited under separate protocols. However, time since diagnosis and age at diagnosis (or age at the time of the survey) were included in the models to minimize bias. Furthermore, our study is cross-sectional and represents a single snapshot in time, thus longitudinal follow-up is critical to determine whether these disparities persist or widen. In addition, given the time between diagnosis and recruitment, there is potential for recall bias. Moreover, our sample size of carriers was limited, because they represented a subset drawn from a much larger unselected population of BC survivors. Nevertheless, we observed clear differences in uptake of RRSO and RRM among black carriers, which requires confirmation and additional longitudinal follow-up. In addition, survey completion rates across racial subgroups was below 30%, which may lead to selection bias, although the study population was comparable to the source population based on available clinical and demographic variables. Also, the sample was confined to Florida and thus may not be generalizable to other parts of the country where clinical practices may vary. Finally, all participants were diagnosed before several practice-changing events that occurred around 2013 and beyond, including plummeting sequencing costs because of technologic advances in conjunction with the fall of the BRCA patent, implementation of the Patient Protection and Affordable Care Act, and celebrity disclosures. 50, 51 To determine whether these changes impacted populations with existing health disparities, more recent studies across ethnically and racially diverse populations of high-risk individuals are needed; this was recently identified as a research gap by the US Preventive Services Task Force. 52 Ultimately, it is critical to better understand the reasons for the lower uptake of cancer risk-management options among black BRCA carriers to develop interventions and assure access to preventive care. In this regard, coverage for genetic testing does not equate to coverage for preventive care, which is essential to improve health outcomes. 53 Consequently, variations in preventive services coverage may exacerbate health disparities without policies to ensure equitable access to these services. Because BRCA testing and cancer risk management are choices, it remains imperative to identify and discuss genetic testing with high-risk individuals across all populations, communicate the information in a culturally congruent and understandable way, and ensure access to testing and follow-up care regardless of socioeconomic factors.
In summary, our study is the first to demonstrate differences in cancer risk-management across black, Hispanic, and NHW women recruited through populationbased efforts. The lower RRSO rates observed among black BRCA carriers are particularly concerning given that most ovarian cancers are diagnosed at a later stage without reliable means for early detection. Furthermore, our findings demonstrate that health care provider discussion was the strongest predictor of testing. Taken together, the underlying etiology of differences observed in testing rates and follow-up care require further study to identify facilitators and barriers. such as psychological, cultural. and geographic factors. In addition to patient-specific factors, provider-level and system-level factors must be examined to develop solutions to narrow existing health disparities in gene-based care. Ultimately, multilevel interventions are needed to reduce the growing health care disparities in clinical cancer genetics.
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